Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
NeuCyte logo — Decoding CNS Drug Discovery with SynFire® iP

NeuCyte

Decoding CNS Drug Discovery with SynFire® iP

Founded 2015 United States Mountain View, United States 11 employees Series A Total: $6.70M Biotechnology, Health Care +2

General Information

Company Name NeuCyte
Founded Year 2015
Location United States Mountain View, United States
Employees 11
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Series A
Business Model B2B, Platform, E Commerce
Revenue Model Project Based, Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with NeuCyte. To contact NeuCyte, visit neucyte.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does NeuCyte compare?

A PDF of NeuCyte and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting NeuCyte soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About NeuCyte

NeuCyte, founded in 2015 and headquartered in the United States, is pioneering advancements in the biotechnology sector with a focus on central nervous system (CNS) drug discovery. Their slogan, "Decoding CNS Drug Discovery with SynFire® iP," encapsulates their mission of refining preclinical testing methodologies. By employing a cutting-edge human neural platform, NeuCyte offers a novel approach that better predicts drug efficacy compared to traditional animal models, thus reducing the costly attrition rates in novel drug trials.

Received in the form of a $6.70M Series A investment on 08 May 2018 from investors Cowin Venture and Leaguer Venture Capital, the company has demonstrated solid growth potential. Its team, comprising top-tier stem cell biologists and neuroscientists, provides a significant competitive advantage. This positions NeuCyte as a noteworthy contender addressing unmet needs in the pharmaceutical and healthcare industries.

Business keywords: CNS Drug Discovery, Neurological Disorders, Neural Cell Technology, Stem Cell Biology, Drug Development, Human Neural Platform, Neurotoxicity Testing, In Vitro Disease Modeling, Lead Compound Optimization, Preclinical Testing, Clinical Trials, Drug Efficacy, Scientific Advisory Board, Neurosciences

Services & Products

Neural Cell Production
Assay Development
Functional Phenotypic Assessment
Custom iPSC-Derived Cell Production
Compound Screening

Target Customers

Biopharmaceutical Companies Neurological Research Institutes Medical Researchers Pharmaceutical Firms Biotech Startups Focusing on Neurological Conditions

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $6.70M 2
Cowin Venture
Cowin Venture, Shenzhen Leaguer Venture Capital
01 May 2018
Seed Undisclosed 1
Wisemont Capital
Wisemont Capital
01 Jul 2016
Spinout Undisclosed 1
Stanford University
01 Jan 2015

NeuCyte Alternatives & Competitors

View All Alternatives
NeuCyte vs
Cellular Dynamics International
Cellular Dynamics International

Harness the Power of Fully Functional Human Cells for Innovative Drug Discovery and Therapeutics.

Debt Financing
Biotechnology, Health Care
NeuCyte vs
StemoniX
StemoniX United States

Pre-plated, human iPSC-derived microOrgans for toxicology and drug discovery research

Convertible Note
1 employees
Biotechnology, Health Care
NeuCyte vs
PsychoGenics
PsychoGenics United States

Discover Your Next Breakthrough

Grant
146 employees
Biotechnology, Health Care
Compare NeuCyte vs PsychoGenics
Also compare with: NeuCyte vs IRLAB Therapeutics AB IRLAB Therapeutics AB View all alternatives

FAQ About NeuCyte

Decoding CNS Drug Discovery with SynFire® iP
NeuCyte was founded in 2015.
NeuCyte is headquartered in Mountain View, United States.
NeuCyte operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on CNS Drug Discovery, Neurological Disorders, Neural Cell Technology and Stem Cell Biology. Its customers include Biopharmaceutical Companies, Neurological Research Institutes and Medical Researchers.
NeuCyte has a B2B, Platform and E Commerce business model. Its revenue comes from Project Based, Product Sales and Licensing.
NeuCyte has approximately 11 employees.
NeuCyte has completed 3 funding rounds, raising a total of $6.70M. The latest funding stage is Series A.
NeuCyte offers: Neural Cell Production, Assay Development, Functional Phenotypic Assessment, Custom iPSC-Derived Cell Production, Compound Screening.
Top alternatives and competitors to NeuCyte include Cellular Dynamics International, StemoniX, PsychoGenics, River BioMedics, Emulate, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NeuCyte and Cellular Dynamics International are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NeuCyte, https://bouncewatch.com/company/neucyte, updated 19 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout